Edward Anders(Andy)KolbMD

PubMed

• 4 citations
  Chronic conditions, late mortality, and health status after childhood AML: a Childhood Cancer Survivor Study report.
  Lucie M Turcotte, Jillian A Whitton, Wendy M Leisenring, Rebecca M Howell, Joseph P Neglia
  Blood. 2023-01-05
• 44 citations
  Evaluation of alternative in vivo drug screening methodology: A single mouse analysis
  Brendan Murphy, Han Yin, John M. Maris, E. Anders Kolb, Richard Gorlick
  Cancer Research. 2016-10-01
• 57 citations
  The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models.
  Nathan M. Kendsersky, Jarrett M. Lindsay, E. Anders Kolb, Malcolm A. Smith, Beverly A. Teicher
  Clinical Cancer Research. 2021-02-22

Journal Articles

• Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis  
  Murphy B, Yin H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Kurmasheva RT, Dvorchik I, Wu J, Billups CA, Boateng N, Smith MA, Lock RB, Houghton PJ, Cancer Res, 1/1/2016
• Initial Testing (Stage 1) of Eribulin, a Novel Tubulin Binding Agent, by the Pediatric Preclinical Testing Program  
  Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Billups CA, Desjardins C, Kurmasheva RT, Houghton PJ, Smith MA, Pediatr Blood Cancer, 1/1/2013
• Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program  
  Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, Arts J, Bashir T, Janicot M, Kurmasheva RT, Houghton PJ, Pediatr Blood Cancer, 1/1/2012
• Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program  
  Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Phelps D, Maris JM, Billups C, Smith MA, Pediatr Blood Cancer, 1/1/2012
• Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program  
  Kang MH, Reynolds CP, Houghton PJ, Alexander D, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Wozniak A, Smith MA, Pediatr Blood Cancer, 1/1/2012
• Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program  
  Morton CL, Maris JM, Keir ST, Gorlick R, Kolb EA, Billups CA, Wu J, Smith MA, Houghton PJ, Pediatr Blood Cancer, 1/1/2012
• Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program  
  Lock RB, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gorlick R, Kolb EA, Houghton PJ, Smith MA, Pediatr Blood Cancer, 1/1/2012
• Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program  
  Kolb EA, Gorlick R, Maris JM, Keir ST, Morton CL, Wu J, Wozniak AW, Smith MA, Houghton PJ, Pediatr Blood Cancer, 1/1/2012
• Initial testing (Stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program  
  Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Billups CA, Smith MA, Pediatr Blood Cancer, 1/1/2012
• Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a gamma-secretase inhibitor targeting notch signaling  
  Kolb EA, Gorlick R, Keir ST, Maris JM, Lock R, Carol H, Kurmasheva RT, Reynolds CP, Kang MH, Wu J, Houghton PJ, Smith MA, Pediatr Blood Cancer, 1/1/2012
• Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program  
  Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Morton CL, Wu J, Smith PG, Yu J, Houghton PJ, Pediatr Blood Cancer, 1/1/2012
• Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program  
  Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJ, Alexander D, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Billups CA, Smith MA, Pediatr Blood Cancer, 1/1/2012
• Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program  
  Gorlick R, Kolb EA, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA, Pediatr Blood Cancer, 1/1/2012
• Progress of oncolytic viruses in sarcomas  
  Lettieri CK, Hingorani P, Kolb EA, Expert Rev Anticancer Ther, 1/1/2012
• Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts  
  Hingorani P, Zhang W, Lin J, Liu L, Guha C, Kolb EA, Cancer, 1/1/2011
• Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program  
  Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ, Pediatr Blood Cancer, 1/1/2011
• Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program  
  Smith MA, Maris JM, Lock R, Kolb EA, Gorlick R, Keir ST, Carol H, Morton CL, Reynolds CP, Kang MH, Houghton PJ, Pediatr Blood Cancer, 1/1/2011
• Initial testing of lenalidomide by the pediatric preclinical testing program  
  Reynolds CP, Kang MH, Keir ST, Gorlick R, Kolb EA, Lock R, Maris JM, Carol H, Morton CL, Billups CA, Smith MA, Houghton PJ, Pediatr Blood Cancer, 1/1/2011
• Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer  
  Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, Morton CL, Gorlick R, Kolb EA, Keir ST, Wu J, Wozniak AE, Yang Y, Manfredi M, Ecsedy J, Wang J, Neale G, Houghton PJ,..., Cancer Chemother Pharmacol, 1/1/2011
• Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program  
  Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gu Y, Wilson WR, Smith MA, Pediatr Blood Cancer, 1/1/2011
• Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program  
  Gorlick R, Maris JM, Houghton PJ, Lock R, Carol H, Kurmasheva RT, Kolb EA, Keir ST, Reynolds CP, Kang MH, Billups CA, Smith MA, Pediatr Blood Cancer, 1/1/2011
• Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program  
  Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP, Kang MH, Maris JM, Keir ST, Kolb EA, Wu J, Wozniak AW, Billups CA, Rubinstein L, Smith MA, Mol Cancer Ther, 1/1/2010
• Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program  
  Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA, Pediatr Blood Cancer, 1/1/2010
• Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program  
  Carol H, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ, Lock RB, Pediatr Blood Cancer, 1/1/2010
• Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program  
  Keir ST, Maris JM, Lock R, Kolb EA, Gorlick R, Carol H, Morton CL, Reynolds CP, Kang MH, Watkins A, Houghton PJ, Smith MA, Pediatr Blood Cancer, 1/1/2010
• Join now to see all

Books/Book Chapters

• AAP Textbook of Primary Care 
  Chapter: Anemia and Pallor 
  Levy AL, Kolb E.A.Editors: Thomas K. McInerny M, FAAP; Henry M. Adam, MD, FAAP; Deborah E. Campbell, MD, FAAP; Deepak M. Kamat, MD, FAAP; and Kelly J. Kelleher, MD, MPH, FAAP.American Academy of Pediatrics2008
• Platelets in Thrombotic and Non-thrombotic Disorders 
  Chapter: Neonatal Alloimmune Thrombocytopenia Purpura 
  Kolb E.A., Bussel J.B.Editors: PA Gresele, J Vermylen, CP Page.Cambridge University Press2002

Abstracts/Posters

• Long Non-Coding RNAs (lncRNAs) Are Highly Associated with Disease Characteristics and Outcome in Pediatric Acute Myeloid Leukemia _ a COG and Tpaml Study
  Edward Anders Kolb, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a ChildrenÍs Onc...
  Anders E. Kolb, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with ...
  Edward Anders Kolb, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Occurrence and Resolution of Anthracycline Cardiotoxicity and Impact on Treatment Outcomes Among Children Treated on the AAML1031 Clinical Trial: A Report from the Chi...
  Edward Anders Kolb, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML
  E. Anders Kolb, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Chronic Health Conditions and Late Mortality Among Survivors of Childhood Acute Myeloid Leukemia: A Report from the Childhood Cancer Survivor Study (CCSS)Clinically Re...
  E. Anders Kolb, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report ...
  Anders E. Kolb, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene _ a COG/Tpaml Study
  E. Anders Kolb, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the ChildrenÍs Oncology Group
  E. Anders Kolb, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction
  E. Anders Kolb, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Discovery and Validation of Cell-Surface Protein Mesothelin (MSLN) As a Novel Therapeutic Target in AML: Results from the COG/NCI Target AML Initiative
  Tarlock K, Kaeding AJ, Alonzo TA, Loken MR, Ries RE, Pardo L, Gerbing R, Farrar JE, Auvil JG, Gerhard DS, Smith MA, Davidsen TM, Gesuwan P, Hermida LC, Marra MA, Munga..., American Society of Hematology, Annual Meeting, 1/1/2016
• Analysis of single mouse tumor response results from the Pediatric Preclinical Testing Program
  Murphy B, Yin H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang M, Keir ST, Kurmasheva R, Dvorchik I, Wu J, Billups C, Smith MA, Houghton PJ, American Association of Cancer Research, Annual Meeting, 1/1/2015
• Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): a report from the Pediatric Preclinical Testing Program
  Smith MA, Lock RB, Carol H, Maris JM, Kang M, Gorlick R, Kolb EA, Keir ST, Wu J, Landesman Y, Schacham S, Lyalin D, Kurmasheva RT, Houghton, PJ, American Association of Cancer Research, Annual Meeting, 1/1/2015
• Combination of epigenetic modifiers achieves complete remission in xenograft models of pediatric acute myeloid leukemia
  Gopalakrishnapilla A, Kolb EA, Barwe SP, American Association of Cancer Research, Annual Meeting, 1/1/2015
• Initial testing (stage 1) of the Curaxin, CBL0137, by the Pediatric Preclinical Testing Program (PPTP)
  Smith MA, Kang M, Reynolds CP, Lock RB, Carol H, Gorlick R, Kolb EA, Maris JM, Keir ST, Billups CA, Kurmasheva RT, Houghton, PJ, American Association of Cancer Research, Annual Meeting, 1/1/2015
• Disruption of annexin II tetramer/receptor axis suppresses leukemia cell homing and engraftment
  Gopalakrishnapilla A, Dhanan P, Kolb EA, Napper A, Mason R, Barwe SP, American Association of Cancer Research, Annual Meeting, 1/1/2014
• Pediatric preclinical testing program (PPTP) evaluation of BMN 673, an inhibitor of poly-adp ribose polymerase (PARP), with temozolomide (TMZ)
  Smith MA, Kang M, Reynolds CP, Gorlick R, Kolb EA, Maris JM, Lock R, Carol H, Keir ST, Billups CA, Kurmasheva RT, Houghton, PJ, American Association of Cancer Research, Annual Meeting, 1/1/2014
• High-throughput screen to identify compounds targeted to embryonal rhabdomyosarcoma harboring mutant HRAS using cells derived from a pediatric Costello syndrome patient
  Cartledge DM, Drake KM, Gripp KW, Sol-Church K, Kolb EA, Napper AD, American Association of Cancer Research, Annual Meeting, 1/1/2013
• Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of the antimicrotubule agents cabazitaxel and docetaxel
  Houghton, PJ, Kang M, Reynolds CP, Lock RB, Carol H, Gorlick R, Kolb EA, Maris JM, Keir ST, Billups CA, Kurmasheva RT, Smith MA, American Association of Cancer Research, Annual Meeting, 1/1/2013
• Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of NSC750854, a sulfamated purine analog with a distinctive anticancer activity profile
  Smith MA, Kang M, Reynolds CP, Gorlick R, Kolb EA, Maris JM, Keir ST, Billups CA, Kurmasheva RT, Houghton, PJ, American Association of Cancer Research, Annual Meeting, 1/1/2013
• Pediatric preclinical testing program (PPTP) stage 1 evaluation of MLN0128, a potent TOR kinase inhibitor
  Houghton, PJ, Kang M, Reynolds CP, Lock RB, Carol H, Gorlick R, Kolb EA, Maris JM, Keir ST, Billups CA, Kurmasheva RT, Smith MA, American Association of Cancer Research, Annual Meeting, 1/1/2013
• Uniparental disomy is associated with embryonal rhabdomyosarcoma in Costello Syndrome and nonsyndromic patients
  Robbins KM, Stabley DL, Conard K, Wu DJ, Stitik H, Kolb EA, Napper A, Mason RW, Gripp KW, Sol-Church K, American Association of Cancer Research, Annual Meeting, 1/1/2013
• Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of the XPO1/CRM1 inhibitor KPT-330
  Houghton, PJ, Kang M, Reynolds CP, Gorlick R, Kolb EA, Maris JM, Keir ST, Carol H, Lock RB, Billups CA, Kurmasheva RT, Landesman Y, Shacham S, Kauffman M, Smith MA, American Association of Cancer Research, Annual Meeting, 1/1/2013
• Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of cabozantinib
  Smith MA, Kang M, Reynolds CP, Gorlick R, Kolb EA, Maris JM, Keir ST, Billups CA, Kurmasheva RT, Houghton, PJ, American Association of Cancer Research, Annual Meeting, 1/1/2013
• Pediatric Preclinical Testing Program (PPTP) evaluation of volasertib (BI 6727), a Polo-like kinase (PLK) inhibitor
  Smith MA, Keir ST, Maris JM, Kolb EA, Reynolds CP, Kang M, Carol H, Lock RB, Gorlick R, Kurmasheva R, Billups C, Houghton PJ, American Association of Cancer Research, Annual Meeting, 1/1/2012
• Join now to see all

Lectures

• Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Immunotherapeutic Targeting of Mesothelin in Acute Myeloid Leukemia in Vitro with Anetumab Ravtansine and a Novel Antibody-Drug Conjugate 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Career-Development Lunch Sessions: Pediatric Clinical Malignant Hematology/BMT 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• Marked Differences in the Genomic Landscape of Pediatric Compared to Adult Acute Myeloid Leukemia: A Report from the Children’s Oncology Group and NCI/COG Therapeutica... 
  1/1/2016
• Acute Myeloid Leukemia: Clinical Studies: Leukemia with Molecular Targets 
  1/1/2016
• Joint Session ECT/AML (session chair) 
  1/1/2016
• Towards Precision Therapy in Childhood AML 
  1/1/2015
• The Past, Present, and Future of Clinical Trial Development in Pediatric AML 
  Nemours Children’s Hospital, Orlando, Florida - 1/1/2015
• The Benefits of Public Cord Blood Banking 
  1/1/2015
• COG YI Develpoment. The Accidental Tourist 
  1/1/2014
• Pediatric Leukemia and Bone Marrow Transplantation 
  1/1/2013
• Progress in Research for Leukemia and Lymphoma 
  1/1/2012
• Cord Blood Banking: rationale and patient counseling 
  1/1/2011
• Oncolytic Virus Therapy in Children 
  1/1/2011
• Palifosfamide, a Bifunctional DNA Alkylator, Inhibits Growth of Pediatric Osteosarcoma Xenografts Across a Wide Dose Range Following Oral and Parenteral Dosing 
  Chicago, IL - 1/1/2011
• Public Cord Blood Banking 
  1/1/2010
• Bereavement Support 
  Philadelphia, PA - 1/1/2010
• A SNP at -216 of the EGFR predicts EGFR-IGF1R cross-talk and resistance to IGF1R inhibition in osteosarcoma 
  1/1/2010
• IGF1R signaling in Osteosarcoma 
  Weill Cornell Medical College - 1/1/2009
• Bone Marrow Transplantation in Children 
  Nemours Alfred I. duPont Hospital for Children, 2007; Riddle Memorial Hospital, 2008 - 1/1/2008
• Hematopoietic Stem Cell Transplantation in Children 
  Brookdale Hospital, 2005; Stamford Health System, 2005 - 1/1/2006
• Relapsed and Refractory Childhood 
  1/1/2006
• Diamond-Blackfan Anemia 
  Montefiore Medical Center - 1/1/2006
• Phase-1/-2 study of ZIO-201 (isophosphoramide mustard (IPM)-lysine) in advanced sarcoma 
  1/1/2006
• A Preclinical Evaluation of ZIO-201 (Isophosphoramide Mustard (IPM)-Lysine) in sarcoma 
  1/1/2006
• Join now to see all

Other

• Hematopoietic Stem Cell Transplantation 
  Powell JL, Hingorani P, Grupp SA, Kolb EA, eMedicine from WebMD
  http://emedicine.medscape.com/article/991032-overview
  1/11/2009
• Familial Mosaic Monosomy 7 Syndrome 
  Morrissette JJD, de Chadarevian JP, Kolb EA, GeneReviews
  http://www.ncbi.nlm.nih.gov/books/NBK45015/
  University of Washington, Seattle - 1/8./2010